Sotevtamab, the novel dual-action agent, is sparking considerable interest within the cancer community, particularly regarding the promise for treating hematologic cancers. The therapy functions by https://jayaprgs513861.mpeblog.com/74651224/sotevtamab-a-emerging-treatment-in-hematologic-malignancies